Technical analysis of Vaxcyte, Inc. (PCVX): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia.
Price Performance
| 1 month | -17.62% |
| 3 months | +3.26% |
| Year-to-date | +31.79% |
| 1 year | +47.06% |
| 3 years | +19.82% |
| 5 years | +140.26% |
52-Week Range
| 52-week High | $90.75 |
| 52-week Low | $39.87 |
| Avg Volume (90d) | 1.8M |
Technical Indicators
| SMA 50 | $61.54 |
| SMA 200 | $57.17 |
| Beta | 1.39 |
| 30-day Volatility (annualised) | 95.2% |
| Price vs SMA 50 | -1.2% |
| Price vs SMA 200 | +6.4% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-12 | $46.14 | |
| 2026-01 | $53.57 | +16.1% |
| 2026-02 | $61.74 | +15.3% |
| 2026-03 | $58.11 | -5.9% |
| 2026-04 | $57.24 | -1.5% |
| 2026-05 | $51.40 | -10.2% |
| 2026-06 | $58.13 | +13.1% |
| 2026-07 | $54.08 | -7.0% |
| 2026-08 | $60.74 | +12.3% |
| 2026-09 | $56.90 | -6.3% |
| 2026-10 | $62.03 | +9.0% |
| 2026-11 | $60.81 | -2.0% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-11-03 | $-2.11 | $12M |
| 2026-08-05 | $-2.06 | $12M |
| 2026-05-06 | $-1.78 | $12M |
| 2026-02-24 | $-1.53 | $19M |
| 2025-11-04 | $-1.27 | |
| 2025-08-06 | $-1.12 | |
Price
| Price | $60.81 (closing price, November 3, 2026) |
| Market Cap | $9.6B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.19 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.04 |
| Current Ratio | 5.72 |
| Piotroski F-Score | 1 |
| Altman Z-Score | 9.02 |